Researchers hypothesized that adverse radiologic and pathologic T3 features are predictive of worse outcomes in small renal masses.
The median cancer-specific survival was 56.5 months.
The monthly incremental cost per survivor relative to sunitinib for nivolumab plus ipilimumab decreased over time from $90,035 for 12 months to $18,881 for 48 months.
Patients with smaller target lesions at baseline were more likely to be long-term survivors.
The investigators aimed to understand how oncologists decide between IO/IO and IO/TKI treatment options via survey.
Nearly half of non-clear cell renal cell carcinoma samples were classified as proliferative.
The median time to first onset of key adverse reactions was within 5 months of starting lenvatinib-pembrolizumab.
Investigators presented the longest phase 3 follow-up reported for a checkpoint inhibitor combination therapy in aRCC.
Researchers determined that few patients with poor risk aRCC were receiving first-line avelumab plus axitinib.
Patients with BAP1-mutant ccRCC have very poor prognosis and comprise 10% to 15% of ccRCC cases.
The rate of new or worsening immune-related adverse events was no higher than previously reported.
No major difference in outcome was observed in a retrospective analysis of patients with mRCC and bone metastasis treated with IO with and without prior radiation.
Investigators assessed the association between DFS and OS in patients with newly diagnosed, completely resected, intermediate-high or high-risk RCC post-nephrectomy.
Iodine concentration and Hounsfield units were associated with treatment response and survival.
It was previously unknown whether the survival benefits seen with lenvatinib plus pembrolizumab persisted in the long term.
A total of 651 patients with clear cell aRCC were randomly assigned to receive nivolumab plus cabozantinib or sunitinib.
The seroconversion rate was 92%.
A retrospective physician-administered chart review evaluated AEs and management strategies used in United States clinical practice among adult patients with aRCC.